NASDAQ: TWST
Twist Bioscience Corp Stock

$38.32-1.36 (-3.43%)
Updated Apr 30, 2025
TWST Price
$38.32
Fair Value Price
N/A
Market Cap
$2.29B
52 Week Low
$30.73
52 Week High
$60.90
P/E
-11.34x
P/B
5.01x
P/S
8.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$330.19M
Earnings
-$197.31M
Gross Margin
44.6%
Operating Margin
-59.58%
Profit Margin
-59.8%
Debt to Equity
0.34
Operating Cash Flow
-$63M
Beta
2.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

TWST Overview

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine TWST's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Diagnostic & Research

Industry Rating
B
TWST
Ranked
#21 of 44

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$77.60A
$42.75A
$1,070.57B
View Top Diagnostic & Research Stocks

Be the first to know about important TWST news, forecast changes, insider trades & much more!

TWST News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TWST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TWST is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TWST is poor value based on its book value relative to its share price (5.01x), compared to the US Diagnostics & Research industry average (3.39x)
P/B vs Industry Valuation
TWST is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TWST due diligence checks available for Premium users.

Valuation

TWST price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-11.34x
Industry
39.05x
Market
29.18x

TWST price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
5.01x
Industry
3.39x
TWST is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TWST's financial health

Profit margin

Revenue
$88.7M
Net Income
-$31.6M
Profit Margin
-35.6%
TWST's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TWST's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$608.6M
Liabilities
$152.6M
Debt to equity
0.34
TWST's short-term assets ($345.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TWST's short-term assets ($345.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TWST's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TWST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$21.4M
Investing
-$1.5M
Financing
$17.9M
TWST's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TWST vs Diagnostic & Research Stocks

TickerZen RatingMarket Cap1d %P/EP/B
TWSTC$2.29B-3.43%-11.34x5.01x
SHCC$3.26B+1.68%71.88x8.05x
GRALC$1.17B-6.28%-0.54x0.47x
NEOGD$1.10B+0.40%-2.26x0.41x
CDNAB$935.59M-6.89%16.88x2.47x

Twist Bioscience Stock FAQ

What is Twist Bioscience's quote symbol?

(NASDAQ: TWST) Twist Bioscience trades on the NASDAQ under the ticker symbol TWST. Twist Bioscience stock quotes can also be displayed as NASDAQ: TWST.

If you're new to stock investing, here's how to buy Twist Bioscience stock.

What is the 52 week high and low for Twist Bioscience (NASDAQ: TWST)?

(NASDAQ: TWST) Twist Bioscience's 52-week high was $60.90, and its 52-week low was $30.73. It is currently -37.08% from its 52-week high and 24.7% from its 52-week low.

How much is Twist Bioscience stock worth today?

(NASDAQ: TWST) Twist Bioscience currently has 59,651,142 outstanding shares. With Twist Bioscience stock trading at $38.32 per share, the total value of Twist Bioscience stock (market capitalization) is $2.29B.

Twist Bioscience stock was originally listed at a price of $14.00 in Oct 31, 2018. If you had invested in Twist Bioscience stock at $14.00, your return over the last 6 years would have been 173.71%, for an annualized return of 18.27% (not including any dividends or dividend reinvestments).

How much is Twist Bioscience's stock price per share?

(NASDAQ: TWST) Twist Bioscience stock price per share is $38.32 today (as of Apr 30, 2025).

What is Twist Bioscience's Market Cap?

(NASDAQ: TWST) Twist Bioscience's market cap is $2.29B, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Twist Bioscience's market cap is calculated by multiplying TWST's current stock price of $38.32 by TWST's total outstanding shares of 59,651,142.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.